Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease

✍ Scribed by Murphy, G.P.; Tjoa, B.A.; Simmons, S.J.; Jarisch, J.; Bowes, V.A.; Ragde, H.; Rogers, M.; Elgamal, A.; Kenny, G.M.; Cobb, O.E.; Ireton, R.C.; Troychak, M.J.; Salgaller, M.L.; Boynton, A.L.

• Publisher: John Wiley and Sons
• Year: 1999
• Tongue: English
• Weight: 225 KB
• Volume: 38
• Category: Article
• ISSN: 0270-4137
• DOI: 10.1002/(sici)1097-0045(19990101)38:1<73::aid-pros9>3.0.co;2-v

✦ Synopsis

Background:

A phase ii trial was conducted to assess the efficacy of infusions of dendritic cells (dc) and two hla-a2-specific psma peptides (psm-p1 and -p2). this report describes thirty three subjects with hormone-refractory metastatic prostate cancer without prior vaccine therapy history who were evaluated and reported as a group.

Methods:

All subjects received six infusions of dc pulsed with psm-p1 and -p2 at six week intervals. clinical monitoring was conducted pre-, during, and post- phase ii study. data collected include: complete blood count, bone and total alkaline phosphatase, prostate markers, physical examination, performance status, bone scan, prostascint scan, chest x-ray, as well as assays to monitor cellular immune responses.

Results:

Six partial and two complete responders were identified in the phase ii study based on npcp criteria, plus 50% reduction of prostate-specific antigen (psa), or resolution in previously measurable lesions on prostascint scan.

Conclusions:

Over 30% of study participants in this group showed a positive response at the conclusion of the trial. this study suggested that dc-based cancer vaccines may provide an alternative therapy for prostate cancer patients whose disease no longer responds to hormone therapy.